| ²é¿´: 552 | »Ø¸´: 1 | ||
| ±¾Ìû²úÉú 1 ¸ö ²©Ñ§EPI £¬µã»÷ÕâÀï½øÐв鿴 | ||
hzlx½ð³æ (³õÈëÎÄ̳)
|
[ÇóÖú]
ÇóÎÄÏ×·ÒëÒ»¶Î
|
|
|
Primary and Secondary Binding Experiments. Radioligand binding assays using cloned GPCRs, ion channels, and transporters were performed using membranes from transiently transfected or stable cell lines as previously detailed(1, 46) through the resources of the National Institute of Mental Health Psychoactive Drug Screening Program. Detailed protocols (including cell handling, buffer composition, assay conditions, etc.) for all assays are available online.(https://pdsp.med.unc.edu/UNC-CH%20Protocol%20Book.pdf) Initial screening assays were performed using a 10-¦ÌM (final concentration)test compound, and the percent inhibition of specific binding by the test compound was determined. When the test compound inhibited >50% of radioligand specific binding, Ki determinations were performed by measuring the inhibition of radioligand binding by various concentrations of test drug (11 concentrations spanning six orders of magnitude). Radioligand binding isotherms were regressed using the One Site Competition Binding function built into Prism 4.0 (GraphPad) to estimate compound IC50 values. Affinity constants (Ki values) were calculated from IC50 values using the Cheng¨CPrusoff approximation. Representative Procedures. |
» ²ÂÄãϲ»¶
0856µ÷¼Á£¬ÊÇѧУ¾ÍÈ¥
ÒѾÓÐ9È˻ظ´
298-Ò»Ö¾Ô¸Öйúũҵ´óѧ-Çóµ÷¼Á
ÒѾÓÐ9È˻ظ´
265Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
ѧУÒѾÌá½»µ½NSFC£¬»¹ÄÜÐÞ¸ÄÂð£¿
ÒѾÓÐ7È˻ظ´
²ÄÁÏѧ˶297ÒѹýËÄÁù¼¶Çóµ÷¼ÁÍÆ¼ö
ÒѾÓÐ6È˻ظ´
295¸´ÊÔµ÷¼Á
ÒѾÓÐ7È˻ظ´
±¾ÈË¿¼085602 »¯Ñ§¹¤³Ì ר˶
ÒѾÓÐ20È˻ظ´
Ò»Ö¾Ô¸ÖÐÄÏ»¯Ñ§337Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
281Çóµ÷¼Á£¨0805£©
ÒѾÓÐ23È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
Çó´óÉñ·ÒëÒ»¶ÎÓ¢ÎÄÎÄÏ×
ÒѾÓÐ1È˻ظ´
ÇóµÂÓïÎÄÏ×·ÒëÒ»¶Î£¨·´Ó¦µÄºó´¦Àí£©
ÒѾÓÐ1È˻ظ´
Çó·ÒëÎÄÏ×µÄÒ»¶Î»°
ÒѾÓÐ5È˻ظ´
Çó·ÒëÒ»¶ÎÈÕÓïÎÄÏ×
ÒѾÓÐ1È˻ظ´
Çó·ÒëÒ»¶ÎÈÕÓïÎÄÏ×
ÒѾÓÐ1È˻ظ´
Çó´óÉñ·ÒëÒ»¶ÎÓ¢ÎÄÎÄÏ×
ÒѾÓÐ0È˻ظ´
Çó·ÒëÒ»¶Î¶íÎÄÎÄÏ×
ÒѾÓÐ2È˻ظ´
Çó·ÒëÒ»¶ÎÎÄÏ×
ÒѾÓÐ6È˻ظ´
Çó·ÒëÎÄÏ×Ò»¶Î£¨Óлú»¯Ñ§£©
ÒѾÓÐ2È˻ظ´
Çó°ï·ÒëÒ»¶ÎÎÄÏ×£¡
ÒѾÓÐ1È˻ظ´
Çó·ÒëÒ»¶ÎÎÄÏ×
ÒѾÓÐ4È˻ظ´
308647707
ľ³æ (ÕýʽдÊÖ)
- ²©Ñ§EPI: 2
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ½ð±Ò: 1884.5
- É¢½ð: 253
- Ìû×Ó: 315
- ÔÚÏß: 72.4Сʱ
- ³æºÅ: 1012551
- ×¢²á: 2010-05-06
- רҵ: ÓлúºÏ³É
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
hzlx(½ð±Ò+80, ²©Ñ§EPI+1): 2011-07-21 23:35:19
|
½áºÏÊ×ÒªºÍ´ÎҪʵÑé·½°¸£¬·ÅÉäÐÔÅäÌå½áºÏʹÓÿË¡GPCRs¼ì²â·¨¡¢Àë×ÓͨµÀºÍתÔË·¨ÓÃÓÚ¶ÌÔÝתȾ»òÎȶ¨Ï¸°ûϵµÄϸ°ûĤ£¬Ïêϸ²ÎÕÕ(1,46)ͨ¹ýÃÀ¹ú¹ú¼Ò¾«ÉñÎÀÉúÑо¿Ôº¹ØÓÚ¾«Éñ´Ì¼¤Ò©Îïɸѡ³ÌÐòµÄ×ÊÔ´¡£ËùÓÐÊÔÑéµÄÏêϸÐÒ飨°üÀ¨Ï¸°û´¦Àí,»º³å×é³É£¬²â¶¨Ìõ¼þµÈ£©¿É²ÎÕÕ.(https://pdsp.med.unc.edu/UNC-CH%20Protocol%20Book.pdf) Ê×ҪɸѡÊÔÑéʹÓÃÒ»¸ö10-¦ÌMµÃ²âÊÔ»¯ºÏÎĩŨ¶È£©£¬ÒÖÖÆ°Ù·Ö±ÈµÄÌØÊâ½áºÏÐÔͨ¹ý²âÊÔ»¯ºÏÎïÀ´¾ö¶¨£¬µ±²âÊÔ»¯ºÏÎïµÄÒÖÖÆ°Ù·Ö±È>50%·ÅÉäÐÔÅäÌåʱ£¬Í¨¹ý¸÷ÖÖŨ¶ÈµÄ²âÊÔÒ©Î11Ũ¶È²ÉÓÃÁù¸öÊýÁ¿¼¶£©²âÁ¿·ÅÉäÐÔÅäÌåµÄÒÖÖÆ°Ù·Ö±ÈÀ´¾ö¶¨Ki£¬·ÅÉäÐÔÅäÌåµÄµÈÎÂÏß·´¸´Ê¹ÓÃÒ»¸öµØÖ·¾ºÕù½áºÏ×÷Óý¨Á¢Àâ¾µ4.0(GraphPad£©À´¹ÀË㻯ºÏÎïIC50 µÄÖµ£¬Ç׺ͳ£Êý£¨KiÖµ£©¿ÉÒÔͨ¹ýCheng¨CPrusoff ½üËÆ·¨µÃµ½µÄIC50Öµ¼ÆËã³öÀ´¡£ Óдú±íÐԵijÌÐò¡£ |
2Â¥2011-07-21 22:44:42













»Ø¸´´ËÂ¥
10